Mymee addresses the gap in the standard of care for autoimmune non-responders


1% of plan members = 20% of Rx costs*
In the US, autoimmune drugs cost over $100B a year and comprise 54% of specialty Rx growth associated with autoimmune biologics and targeted therapies. However, on average, 40% of rheumatic patients are non-responders in clinical trials and over 70% do not sustain remission in the real world. These patients remain at risk of exposure to unique sensitivities in their exposome that drive worsening symptoms despite prescribed medication.
*Sources: Prime Therapeutics, Inc, CVS Payor Solutions, Published meta analysis of RA, PsA, AS IBM claims data, real world evidence studies & RCTs
Mymee’s proprietary, personalized trial & care platform improves patient outcomes to deliver proven & measurable value impact for payers
.png?width=29&height=64&name=Layer%203%20(2).png)
Average gross annual Rx savings of $11,328 per patient on biologics defined by payer audited script reduction

Statistically significant and clinically meaningful change among symptomatic patients across 10 HRQoL domains as measured by PROMIS-29. The more severe the symptom, the greater the average improvement

> 40% mean reduction in 59 patient-reported symptoms surveyed in personalized trials

Reduction in average # of prescription drugs among patients who were symptomatic at baseline
Learn more about supporting autoimmune patients through personalized trial & care
Read on for additional articles and insights related to Mymee’s research and use of coach-led personalized trials to guide statistically significant improvements in quality of life.

.png)
PR Newswire: Mymee's Personalized Trial & Care Platform Helps Autoimmune Disease Patients Reverse Flares, New Research Shows

Rheumatology Network: Self-Advocacy Platform Allows Patients with Autoimmune Diseases to Discover Triggers, Improve Disease Management

PR Newswire: New Real-world Study Demonstrates Connection Between
Long COVID and Rheumatic Autoimmune Disease Symptoms and Environmental Triggers
